- Home
- ANAB vs IAUX Comparison
ANAB vs IAUX Comparison
Compare ANAB & IAUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ANAB | IAUX |
|---|---|---|
| Founded | 2005 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | 2015 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ANAB | IAUX |
|---|---|---|
| Price | $48.43 | $1.61 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 2 |
| Target Price | ★ $88.50 | $3.53 |
| AVG Volume (30 Days) | 441.4K | ★ 6.8M |
| Earning Date | 09-21-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.02 | 11.76 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $234,603,000.00 | $95,193,000.00 |
| Revenue This Year | $17.97 | $108.00 |
| Revenue Next Year | $36.88 | $81.33 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 157.01 | 89.12 |
| 52 Week Low | $29.49 | $0.89 |
| 52 Week High | $73.30 | $2.24 |
Technical Indicators
Market Signals| Indicator | ANAB | IAUX |
|---|---|---|
| Relative Strength Index (RSI) | 33.62 | 44.76 |
| Support Level | $49.93 | $1.59 |
| Resistance Level | $51.67 | $1.65 |
| Average True Range (ATR) | 2.07 | 0.07 |
| MACD | -0.37 | -0.02 |
| Stochastic Oscillator | 13.66 | 9.62 |
Price Performance
Historical ComparisonAbout ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About IAUX i-80 Gold Corp.
i-80 Gold Corp is a well-financed gold and silver producer engaged in the exploration, development, and production of gold, silver, and poly-metallic deposits. The Company's principal assets include the Ruby Hill Mine, Lone Tree Mine, Granite Creek Mine, and McCoy-Cove Project.